Director Scott T. Garrett of HCW Biologics Inc. (NASDAQ:HCWB) recently engaged in substantial transactions involving the company's equity. On May 22, 2026, Mr. Garrett acquired 177,936 shares of the firm’s common stock. The purchase was executed at a price point of $1.405 per share, resulting in a total outlay of $250,000.
Furthermore, on that same date, Mr. Garrett also acquired 177,936 common stock purchase warrants. These warrants carry an exercise price set at $1.28 per share and are scheduled to expire on November 22, 2031. Each warrant grants the holder the right to obtain one share of HCW Biologics common stock.
It is important to note that both the acquisition of the common stock shares and the warrants were completed indirectly through a Limited Liability Company (LLC). These transactions constituted part of a private placement originating directly from the issuer, which qualifies for an exemption under certain provisions of the Securities Exchange Act of 1934.
While the company has reported a year-to-date return of 99.88%, analysis also points to high price volatility in the stock. The current trading price is $1.95, and according to InvestingPro’s Fair Value assessment, HCWB appears undervalued based on its metrics.
Recent Corporate Developments at HCW Biologics
In addition to the director's activity, HCW Biologics Inc. has announced several notable corporate developments that underscore its operational and financial momentum.
- Licensing Agreements: The company received a significant upfront license fee of $7 million from Beijing Trimmune Biotech Co., Ltd. This payment structure included both a $3.5 million cash component and a corresponding $3.5 million equity stake.
- Financing Round: HCW Biologics successfully completed a separate private placement valued at $4 million, with E.F. Hutton & Co. acting as the exclusive placement agent for the transaction.
- Intellectual Property Rights: The company regained full ex vivo rights to two key compounds, HCW9206 and HCW9201, from Wugen Inc. As part of this recovery, HCW Biologics retained a nonrefundable upfront license fee and 2.2 million shares of Wugen common stock.
On the front end of product development, HCW Biologics plans to submit an Investigational New Drug (IND) application in 2027. This filing will concern HCW11-018b, a T-cell engager designed for treating pancreatic cancer and other solid tumors.
Operational Timeline and Corporate Governance
Regarding corporate governance, HCW Biologics recently had to adjourn its Special Meeting of Stockholders due to insufficient quorum. Consequently, the matters originally slated for that meeting have been postponed until the company's Annual Meeting of Stockholders scheduled for June 2026.
The market data indicates varying price movements. The stock closed at $1.75 and reached a high of $2.25 during the observed period, showing fluctuations throughout the day's trading hours. After-hours trading saw an increase to $2.06 (+0.120 or +6.19%), following a closing price of $1.95.
Analysis and Outlook
These combined transactions, including the director's investment, major licensing deals, private financing, IP rights recovery, and future IND filing plans, collectively highlight multiple strategic moves by HCW Biologics in the areas of licensing, financial capitalization, and pipeline advancement. The company continues to develop its focus on solid tumor treatments.